What is Pheon Therapeutics?
Pheon Therapeutics is a biotechnology firm dedicated to the advancement of Antibody Drug Conjugates (ADCs). By focusing on novel targets and innovative payloads, the company is building a robust pipeline of monotherapies designed to treat solid tumors and liquid cancers that have historically proven resistant to conventional therapeutic approaches. The firm's lead program represents a first-in-class ADC, targeting highly expressed markers in a broad range of hard-to-treat cancer types. Positioned at the intersection of precision medicine and oncology, Pheon Therapeutics leverages deep scientific expertise to translate complex biological insights into viable, life-changing medical solutions.
How much funding has Pheon Therapeutics raised?
Pheon Therapeutics has raised a total of $188M across 2 funding rounds:
Series A
$68M
Series B
$120M
Series A (2022): $68M with participation from Atlas Venture, Forbion, and Brandon Capital
Series B (2024): $120M led by TCG Crossover, Lightspeed Venture Partners, and Forbion
Key Investors in Pheon Therapeutics
TCG Crossover
TCG Crossover is a science-driven investment firm focused on advancing disruptive medicines and supporting breakthrough therapies that have the potential to transform healthcare.
Lightspeed Venture Partners
Lightspeed Venture Partners is a global multistage venture capital firm that invests in early and growth-stage technology and life science companies, partnering with founders from inception through IPO.
Forbion
Forbion is a global life sciences venture capital firm with a strong track record of guiding biotech and biopharmaceutical companies from early-stage research through clinical development.
What's next for Pheon Therapeutics?
With the capital secured in this latest round, Pheon Therapeutics is well-positioned to accelerate its clinical development programs. The strategic focus will likely shift toward advancing its lead ADC candidate through critical trial phases, while simultaneously expanding its pipeline of novel targets. As the company scales its operations, the emphasis will remain on validating the efficacy and safety of its therapeutic platform. Given the current enterprise-level funding context, the firm is expected to strengthen its internal R&D capabilities and potentially explore strategic partnerships to enhance its market reach and accelerate the path to commercialization for its oncology portfolio.
See full Pheon Therapeutics company page
